Predicting disease progression in primary membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is testing a tool that uses patient information to predict how quickly primary membranous nephropathy (a kidney disease) may progress. If you join, your data may help doctors better understand and plan treatment for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a kidney biopsy that confirms primary membranous nephropathy.
- You cannot have secondary membranous nephropathy, which means your kidney disease is not caused by another condition such as lupus, hepatitis B or C, cancer, or certain medications.
- You cannot be pregnant.
- You cannot have end-stage kidney disease (kidney failure) at the time you start the study.
- You must be willing to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
This study looks at blood and tissue samples from people with membranous nephropathy, a kidney disease, to find biological markers that predict whether rituximab, a treatment, will work. The goal is to understand why some patients do not respond, which could lead to better personalized treatment.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This study examines blood and kidney tissue samples from people with membranous nephropathy—a condition where the kidney's filtering membrane is damaged by the immune system. Researchers are trying to understand which immune markers predict how the disease will progress and respond to treatment.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.